Depth of response (DepOR) analysis and correlation with clinical outcomes from JAVELIN Renal 101.

Martin H  Voss

Stock and Other Ownership Interests  - CellGenix (I)

Consulting or Advisory Role - Alexion Pharmaceuticals; Calithera Biosciences; Corvus Pharmaceuticals; Eisai; Exelixis; GlaxoSmithKline; Novartis; Pfizer

Research Funding - Bristol-Myers Squibb; Genentech/Roche; Pfizer

Travel, Accommodations, Expenses - AstraZeneca; Eisai; Takeda

Robert J.  Motzer

Consulting or Advisory Role - Eisai; Exelixis; Genentech/Roche; Incyte; Lilly; Merck; Novartis; Pfizer

Research Funding - Bristol-Myers Squibb (Inst); Eisai (Inst); Genentech/Roche (Inst); Novartis (Inst); Pfizer (Inst)

Laurence  Albiges

Consulting or Advisory Role - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Corvus Pharmaceuticals (Inst); Exelixis (Inst); Ipsen (Inst); Merck (Inst); MSD (Inst); Novartis (Inst); Novartis (Inst); Peloton therapeutics (Inst); Pfizer (Inst); Roche (Inst)

Research Funding - Bristol-Myers Squibb (Inst)

Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD

Brian I.  Rini

Leadership - MJH Life Sciences

Consulting or Advisory Role - AVEO; Bristol-Myers Squibb; Merck; Peloton Therapeutics; Pfizer; Roche/Genentech; Surface Oncology; synthorx

Research Funding - AstraZeneca/MedImmune (Inst); AVEO (Inst); Bristol-Myers Squibb (Inst); Merck (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Roche/Genentech (Inst)

Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck; Pfizer

Manuela  Schmidinger

Honoraria - Bristol-Myers Squibb; Eisai; EUSA Pharma; Ipsen; MSD Oncology; Pfizer; Roche/Genentech

Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; EUSA Pharma; Ipsen; MSD Oncology; Pfizer; Roche

Travel, Accommodations, Expenses - Bristol-Myers Squibb; Ipsen; Roche

James M. G.  Larkin

Honoraria - Achilles Therapeutics; AstraZeneca; Boston Biomedical; Bristol-Myers Squibb; Eisai; EUSA Pharma; GlaxoSmithKline; Imugene; Incyte; iOncologi; Ipsen; Kyocera; Merck Serono; MSD; Nektar; Novartis; Pfizer; Pierre Fabre; Roche/Genentech; Sectra; Vitaccess

Consulting or Advisory Role - Achilles Therapeutics; AstraZeneca; Boston Biomedical; Bristol-Myers Squibb; Eisai; EUSA Pharma; GlaxoSmithKline; Imugene; Incyte; iOncologi; Ipsen; Kyocera; Merck Serono; MSD; Nektar; Novartis; Pfizer; Pierre Fabre; Roche/Genentech; Sectra; Vitaccess

Research Funding - Achilles Therapeutics (Inst); AVEO (Inst); Bristol-Myers Squibb (Inst); Covance (Inst); Immunocore (Inst); MSD (Inst); Nektar (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)

Travel, Accommodations, Expenses - Bristol-Myers Squibb; Novartis; Pfizer; Roche/Genentech

John B. A. G.  Haanen

Consulting or Advisory Role - Bristol-Myers Squibb (Inst); MSD Oncology (Inst); Neon Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)

Research Funding - Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); MSD (Inst)

Christian K.  Kollmannsberger

Honoraria - Bristol-Myers Squibb; Novartis; Pfizer

Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; Eisai; Ipsen; Janssen; Novartis; Pfizer

Travel, Accommodations, Expenses - Eisai; Novartis; Pfizer

Matthew T.  Campbell

Honoraria - Eisai; EMD Serono; Genentech/Roche; Pfizer; Taiho Pharmaceutical

Consulting or Advisory Role - Apricity Health; AstraZeneca; Eisai; EMD Serono; Genentech; Novartis; Pfizer

Research Funding - Exelixis

Marc-Oliver  Grimm

Honoraria - Apogepha; Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Medac; MSD; Novartis; Ono Pharmaceutical; Pfizer

Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer Health; Bristol-Myers Squibb; Hexal; Intuitive Surgical; Ipsen; Janssen-Cilag; Merck; MSD; Novartis; Ono Pharmaceutical; Pfizer; Roche

Research Funding - Bristol-Myers Squibb (Inst); Intuitive Surgical (Inst)

Travel, Accommodations, Expenses - Bayer Health; Bristol-Myers Squibb; Merck Serono

Sumanta K.  Pal

Honoraria - Astellas Pharma; Medivation; Novartis

Consulting or Advisory Role - Astellas Pharma; Aveo; Bristol-Myers Squibb; Eisai; Exelixis; Genentech; Ipsen; Myriad Pharmaceuticals; Novartis; Pfizer

Research Funding - Medivation

Gwenaelle  Gravis

Travel, Accommodations, Expenses - Astellas Pharma; Bristol-Myers Squibb; Ipsen; Janssen Oncology; Pfizer; Sanofi

Michael B.  Atkins

Honoraria - Merck

Consulting or Advisory Role - Agenus; Array BioPharma; Arrowhead Pharmaceuticals; Aveo; Bristol-Myers Squibb; Cota Healthcare; Eisai; Exelixis; Fathom Biotechnology; Genentech; Glactone Pharma; Immunocore; Iovance Biotherapeutics; Leads Biolabs; Merck; Novartis; Oncolys BioPharma; Pfizer; Pneuma Respiratory; Pyxis; Surface Oncology; Werewolf Pharma; X4 Pharma

Research Funding - Bristol-Myers Squibb (Inst)

Bo  Huang

Employment - Pfizer

Stock and Other Ownership Interests  - Pfizer

Aleksander  Chudnovsky

No Relationships to Disclose

Alessandra  di Pietro

No Relationships to Disclose

Despina  Thomaidou

Employment - Pfizer

Stock and Other Ownership Interests  - Pfizer

Toni K.  Choueiri

Employment - Dana Farber Cancer Hospital

Leadership - ASCO; Dana Farber Cancer Hospital; Kidney Cancer Association; KidneyCan; NCCN

Stock and Other Ownership Interests  - Pionyr; Tempest Therapeutics

Honoraria - Alexion Pharmaceuticals; alligent; Analysis Group; ASCO; AstraZeneca; Bayer; Bristol-Myers Squibb; Cerulean Pharma; Clinical Care Options; Corvus Pharmaceuticals; Eisai; EMD Serono; Exelixis; Foundation Medicine; Genentech/Roche; GlaxoSmithKline; Harborside Press; HERON; Ipsen; Kidney Cancer Association; Lancet Oncology; Lilly; Lpath; Merck; Michael J. Hennessy Associates; Navinata Health; NCCN; Novartis; Peloton Therapeutics; Pfizer; PlatformQ Health; Prometheus; Sanofi/Aventis; The New England Journal of Medicine; UpToDate

Consulting or Advisory Role - Alexion Pharmaceuticals; alligent; Analysis Group; ASCO; AstraZeneca; Bayer; Bristol-Myers Squibb; Cerulean Pharma; Clinical Care Options; Corvus Pharmaceuticals; Eisai; EMD Serono; ESMO; Exelixis; Foundation Medicine; GlaxoSmithKline; Harborside Press; HERON; Ipsen; Kidney Cancer Association; Lancet Oncology; Lilly; Lpath; Merck; Michael J. Hennessy Associates; Navinata Health; NCCN; Novartis; Peloton Therapeutics; Pfizer; PlatformQ Health; Prometheus; Roche/Genentech; Sanofi/Aventis; The New England Journal of Medicine; UpToDate

Research Funding - Agensys (Inst); Analysis Group (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); CDMRP/DOD (Inst); Celldex (Inst); Cerulean Pharma (Inst); Corvus Pharmaceuticals (Inst); Eisai (Inst); Exelixis (Inst); Foundation Medicine (Inst); Gateway for Cancer Research (Inst); GlaxoSmithKline (Inst); Ipsen (Inst); Merck (Inst); NCI (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Prometheus (Inst); Roche (Inst); Roche/Genentech (Inst); Seattle Genetics/Astellas (Inst); Takeda (Inst); TRACON Pharma (Inst)

Travel, Accommodations, Expenses - in relation to consultancy/ad boards

Other Relationship - Medical writing and editorial assistance support may have been funded by Communications companies funded by pharmaceutical companies such as ClinicalThinking, Health Interactions, Envision Pharma Group, Fishawack Group of Companies, Parexel